Für Sie gelesen: Tocilizumab (TCZ) Monotherapy is Superior to Adalimumab (ADA) Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis (RA): 24-Week Data from the Phase 4 ADACTA Trial

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text